Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings
Please find all content at the link.
patient
Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies
Curing the Incurable: TP53 Mutated Myeloid Neoplasms
Abstract
Imetelstat
Who should not take RYTELO?
Before taking RYTELO, tell your healthcare provider about all your medical conditions, including if you:
Understanding Brain Fog, Chemo Brain, with Dr. Jorg Dietrich
In this webinar, Dr. Jorg Dietrich will discusses the diagnosis of brain fog/chemo brain and how patients can manage this symptom of disease and its treatments.
Advances in Transplant and GVHD with Dr. Corey Cutler
In this webinar, Dr. Corey Cutler discusses advances in transplant and treating GVHD, or Graft Versus Host Disease.
Managing PNH Complications Webinar
In this webinar, Dr. Srinivasa Sanikommu discusses the management of PNH and complications experienced by patients.
What is PNH? Webinar
In this webinar, Dr. Srinivasa Sanikommu discusses the diagnosis of PNH and current treatments available to patients.
IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML
A clinical guide to TP53 mutations in myeloid neoplasms
TP53 mutations are found in 10-15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multi-hit TP53 mutant myeloid neoplasms having a very poor prognosis. Significant differences exist among the methods used in clinical and research settings to assess TP53 mutational status, leading to variability in reported patient characteristics, response to therapy, and survival.